Meningococcal Vaccines in United States to 2022

211 views

Published on

Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
211
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Meningococcal Vaccines in United States to 2022

  1. 1. PharmaPoint: Meningococcal Vaccines - United States Drug Forecast and Market Analysis to 2022 GlobalData has released its new Country report, PharmaPoint: Meningococcal Vaccines United States Drug Forecast and Market Analysis to 2022. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofis Menactra and Novartis Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment. GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022. GlobalData expects the MenACWY patient share to remain stagnant because of the markets high level of maturity. In contrast, the MenB vaccine market appears poised to take off in the US. GlobalData anticipates that Pfizer will target adolescents with its MenB vaccine, an approach that should facilitate rapid uptake, given the ACIPs current immunization recommendations (CDC, 2013b). On the other hand, the reluctance of policymakers to implement a routine infant program that does not offer serogroup B protection poses a challenge to companies that have targeted this age segment, such as GSK. Scope Overview of Meningococcal Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for the top drugs in the US from 2012-2022. Analysis of the impact of key events as well the drivers and restraints affecting the US Meningococcal Vaccines market. Reasons to buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Meningococcal Vaccines Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of drug performance Obtain sales forecast for drugs from 2012-2022 in the US table Of Contents 1 Table Of Contents 1 1.1 List Of Tables 3 1.2 List Of Figures 3 2 Executive Summary 4 PharmaPoint: Meningococcal Vaccines - United States Drug Forecast and Market Analysis to 2022
  2. 2. 2.1 Sales For Meningococcal Vaccine In The Us 4 2.2 What Do The Physicians Think? 6 3 Introduction 7 3.1 Catalyst 7 3.2 Related Reports 8 3.3 Upcoming Related Reports 10 4 Disease Overview 10 4.1 Etiology And Pathophysiology 11 4.1.1 Etiology 11 4.1.2 Pathophysiology 12 4.2 Symptoms 14 4.3 Prognosis 14 5 Disease Management 15 5.1 Meningococcal Immunization Policy 16 5.2 Us 18 5.2.1 Meningococcal Immunization Recommendations And Policies 18 5.2.2 Clinical Practice 21 6 Competitive Assessment 22 6.1 Overview 22 6.2 Strategic Competitor Assessment 22 6.3 Product Profiles Major Brands 24 6.3.1 Menactra 24 6.3.2 Menveo 29 6.3.3 Menhibrix 33 6.3.4 Menomune 37 6.3.5 39 7 Opportunity And Unmet Need 39 7.1 Overview 39 7.2 Unmet Needs 40 7.2.1 Unmet Need: Protection Against Serogroup B Disease 40 7.2.2 Unmet Need: A Pentavalent (menabcwy) Vaccine 40 7.2.3 Unmet Need: More Cost-effective Vaccines 42 7.2.4 Unmet Need: Improved Duration Of Immunity In Children And Adolescents 42 PharmaPoint: Meningococcal Vaccines - United States Drug Forecast and Market Analysis to 2022
  3. 3. 7.2.5 Unmet Need: Immunogenic Infant Vaccines 44 7.2.6 Unmet Need: Improved Vaccination Coverage Rates 45 7.2.7 Unmet Need: Increased Patient Awareness And Education 46 7.3 Unmet Needs Gap Analysis 47 7.4 Opportunities 48 7.4.1 Opportunity: Broadening Serogroup Protection With New And Existing Antigen Combinations 48 7.4.2 Opportunity: Improving Immune Response Duration With Adjuvants 49 7.4.3 Opportunity: Developing More Cost-effective Vaccines By Partnering With Manufacturers In Emerging Markets 50 8 Pipeline Assessment 50 8.1 Overview 50 8.2 Promising Vaccines In Clinical Development 50 8.2.1 Mnb Rlp2086 54 8.3 Promising Vaccines In Early Clinical Development 58 8.3.1 Meninge Acyw Conj. 59 8.3.2 Menabcwy 63 8.3.3 Menc Conjugate 66 8.3.4 Heptavalent Dtp-hib-hepb-ipv-menc 69 9 Market Outlook 71 9.1 United States 71 9.1.1 Forecast 71 9.1.2 Key Events 75 9.1.3 Drivers And Barriers 76 10 79 11 Appendix 79 11.1 Bibliography 79 11.2 Abbreviations 90 11.3 Methodology 92 11.4 Forecasting Methodology 92 11.4.1 Vaccine Coverage 93 11.4.2 Vaccine Approval Vs. Routine Schedule Inclusion 93 11.4.3 Vaccines Included 94 11.4.4 Key Launch Dates 95 11.4.5 General Pricing Assumptions 96 11.4.6 Individual Vaccine Assumptions 97 PharmaPoint: Meningococcal Vaccines - United States Drug Forecast and Market Analysis to 2022
  4. 4. 11.4.7 Pricing Of Pipeline Agents 99 11.5 Physicians And Specialists Included In This Study 100 11.6 About The Authors 103 11.6.1 Authors 103 11.6.2 Reviewers 103 11.6.3 Global Head Of Healthcare 104 11.7 About Globaldata 105 11.8 Contact Us 105 11.9 Disclaimer 105 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ PharmaPoint: Meningococcal Vaccines - United States Drug Forecast and Market Analysis to 2022

×